BB Biotech

BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.[10] The company invests mainly in the US and Western Europe.[11] BB Biotech is managed by Bellevue Asset Management, a division of Bellevue Group[12] and accounts for approximately 40% of the Group's Assets Under Management.[13]

BB Biotech AG
TypeAktiengesellschaft
SIX: BION[1]
FWB: BBZA[2]
Euronext: BIO.MI[3]
IndustryInvestments
Founded9 November 1993 (9 November 1993)[4]
HeadquartersSchaffhausen, Switzerland[5]
Key people
Erich Hunziker
(Chairman)[6]
Daniel Koller
(Head Investment Management)[7]
ProductsInvestment in biotechnology companies
CHF 691 million
(31 December 2020)[8]
Total assetsCHF 4.357 billion
(30 June 2021)[9]
Websitewww.bbbiotech.ch

Investment activities

As a closed-end fund, specialising in biotech sector,[14] BB Biotech is the oldest-established[13] and largest entity.[12] Over the long term, the company counts to the best performers within its peer group.[12] Over the last decade leading to 2020, it consistently met its own aim to deliver 15% of annual growth in capital[13] including a 5% dividend per year.[12]

With a focus on US small-to-mid-cap biotech companies[15] developing therapeutic products,[14] BB Biotech investmets mainly concentrate on cell, gene and particularly RNA-based technologies.[13]

History

Daniel Koller and Dallas J. Webb are the fund managers.[11] BB Biotech AG mainly invests in the fields of oncology, cardiovascular diseases, metabolic diseases, infectious diseases and autoimmune diseases. Its portfolio includes 20-35 companies, including Celgene, Actelion, Vertex Pharmaceuticals, Gilead Sciences, Novo Nordisk, Incyte, Isis Pharmaceuticals, ImmunoGen, Halozyme Therapeutics, Ariad Pharmaceuticals, BioMarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin Limited, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug and Idenix Pharmaceuticals.[16]

In December 2016 the company launched BB Healthcare Trust, an investment trust focused on biotech companies.[17]

As of December 31, 2019 the seven core investments in the BB Biotech portfolio were: Ionis Pharmaceuticals (13.5% of the BB Biotech Portfolio); Neurocrine Biosciences (9.5%); Incyte (8.2%); Vertex Pharmaceuticals (7.5%), Esperion Therapeutics (6.1%); Agios Pharmaceuticals (5.1%), Alnylam Pharmaceuticals (5.1%)[18]

Company Figures

Company figures are as follows:[19][20]

(figures in millions CHF) 2020 2019 2018 2017 2016 2015
Profit/(Loss) 691.2[8][21] 677.4 (471.3) 687.5 (802.1) 652.8
Net asset value 3'887.5[21] 3'393.0 2'884.5 3'538.7 3'003.0 3'978.2
Market capitalization 4107.9[22][21] 3'670.3 3'235.4 3'576.1 3'052.5 3'463.2

References
  1. Editorial, Reuters. "BION.S - BB BIOTECH AG All Listings | Reuters". www.reuters.comundefined. Retrieved 20 October 2021.
  2. "BB Biotech AG Equity | A0NFN3 | CH0038389992 | Share Price". www.boerse-frankfurt.de. Retrieved 20 October 2021.
  3. "Bb Biotech Stocks Quotes: Company Profile - Borsa Italiana". www.borsaitaliana.it. Retrieved 20 October 2021.
  4. AG, DV Bern. "BB Biotech AG". Official Companies Register of the Canton of Schaffhausen (in German). Retrieved 20 October 2021.
  5. "BB Biotech AG. Zentraler Firmenindex". www.zefix.ch (in German). Retrieved 20 October 2021.
  6. "BB BIOTECH - About us. Board of Directors". www.bbbiotech.ch. Retrieved 20 October 2021.
  7. "BB BIOTECH - About us. Team". www.bbbiotech.ch. Retrieved 20 October 2021.
  8. "BB Biotech AG, BION:SWX financials - FT.com". markets.ft.com. Retrieved 20 October 2021.
  9. "Consolidated balance sheet - Interim report as at 30.06.2021". BB Biotech - Quarter Report 2021/2. Retrieved 20 October 2021.
  10. "BB Biotech". Borsa Italiana. Retrieved 3 June 2020.
  11. "BB Biotech AG". Bloomberg. Retrieved 15 April 2021.
  12. QuotedData by Marten & Co (11 February 2021). "BB Biotech AG. A leading biotech investor" (pdf). Retrieved 7 November 2021.
  13. "BB Biotech AG - A leading biotech investor". QuotedData. 11 February 2021. Retrieved 7 November 2021.
  14. "BB Analysis - BB Biotech AG Fund - Bloomberg Markets". www.bloomberg.com. Bloomberg. Retrieved 7 November 2021.
  15. "BB Biotech AG, BION:SWX profile - FT.com". markets.ft.com. Retrieved 7 November 2021.
  16. "BB Biotech AG (BION) CHF1". Hargreaves Lansdown. 15 January 2021. Retrieved 19 April 2021.
  17. "Star BB Biotech manager steps back from Healthcare trust". City Wire. 25 March 2019. Retrieved 3 June 2019.
  18. "BB Biotech Portfolio". BB Biotech. 11 March 2020.
  19. finanzen.net Retrieved 1st of January 2016.
  20. "BB Biotech - Facts & Figures". BB Biotech. 11 March 2020.
  21. "BB BIOTECH -Facts & Figures". www.bbbiotech.ch. Retrieved 20 October 2021.
  22. "BB Biotech - Annual Report 2020". BB Biotech - Annual Report 2020. Retrieved 20 October 2021.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.